- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02661542
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
April 5, 2022 updated by: Fujifilm Pharmaceuticals U.S.A., Inc.
A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas
A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and Lymphomas.
A total of up to 9 cohorts will be enrolled in Phase 1 to establish the MTD.
Phase 2 will consist of 2 cohorts: Cohort 1 will include subjects with Pancreatic Cancer.
Cohort 2 will include subjects with another tumor type enrolled in the Phase 1 dose-escalation phase who have demonstrated Clinical Benefit by Week 16.
Study Overview
Detailed Description
Subjects will receive doses of FF-10502-01 intravenously (IV) weekly for three weeks, repeated every 28 days (= 1 cycle).
Disease assessments, based on computed tomography (CT), magnetic resonance image (MRI), and, for lymphoma, [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) scans, will be obtained at Week 8 and every 8 weeks thereafter until documented progression of disease (PD).
Subjects who demonstrate clinical benefit will be allowed to continue therapy with FF-10502-01 until progression of disease, observation of unacceptable adverse events, intercurrent illness or changes in the subject's condition that prevents further study participation.
Study Type
Interventional
Enrollment (Actual)
99
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Sarah Cannon Research Institute at HealthONE
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females ≥ 18 years of age
- Histologically or cytologically confirmed advanced or metastatic solid tumor or l lymphoma, that is refractory to standard therapy, relapsed after standard therapy, or for which no standard therapy available that is expected to improve survival by at least three months
- At least 4 weeks beyond the last chemotherapy (or ≥ 5 half-lives for targeted agents, whichever is shorter), radiotherapy, major surgery or experimental treatment and recovered from all acute toxicities (≤ Grade 1)
- Adequate performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2
- Life expectancy of ≥ 3 months
- Adequate hematologic parameters without ongoing transfusional support:
- Hemoglobin (Hb) ≥ 9 g/dL
- Absolute neutrophil count (ANC) ≥ 1.0 x 109 cells/L
- Platelets ≥ 100 x 109 cells/L
- Adequate renal and hepatic function:
- Creatinine ≤ 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance ≥ 60 mL/minute x 1.73 m2 per the Cockcroft-Gault formula
- Total bilirubin ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's disease
- ALT/AST ≤ 2.5 times ULN, or < 5 times ULN for subjects with liver metastases
- QT interval corrected for rate (QTc) ≤ 480 msec on the electrocardiogram (ECG) obtained at Screening
- Negative serum pregnancy test within 14 days prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months). Sexually active WCBP and male subjects must agree to use adequate methods to avoid pregnancy (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study and for 28 days after the completion of study treatment.
- Ability to provide written informed consent
Exclusion Criteria:
- Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV
- Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, with the exception of anti-microbials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for patient care
- Active central nervous system (CNS) malignant disease in subjects with a history of CNS malignancy. Subjects with stable, prior or currently treated brain metastases are allowed.
- Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)
- Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment
- Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
- Pregnant or breast-feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1: Lowest dose of FF-10502-01
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 1: 1.5x lowest dose of FF-10502-01
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 1: 2.25x lowest dose of FF-10502-01
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 1: 3.375x lowest dose of FF-10502-01
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 1: 5x lowest dose of FF-10502-01
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 1: 7.5x lowest dose of FF-10502-01
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 1: 11.25x lowest dose of FF-10502-01
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 1: 16.875x lowest dose of FF-10502-01
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 1: 25x lowest dose of FF-10502-01
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 2a: FF-10502-01 at MTD in Pancreatic Cancer
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
|
Experimental: Phase 2a: FF-10502-01 at MTD in Solid Tumors
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle.
The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)
Time Frame: 33 Months
|
Safety and tolerability assessed by adverse events (AEs), and serious adverse events.
(SAEs)
|
33 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of overall response rates
Time Frame: Responses assessed at end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug (every 28 days=1 cycle).
|
Determination of overall response rates
|
Responses assessed at end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug (every 28 days=1 cycle).
|
Determination of duration of response.
Time Frame: Assessed at end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug
|
duration of response is determined
|
Assessed at end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug
|
Determination of duration of stable disease (SD) as measured from time of 1st evidence of response to time of 1st evidence of progressive disease as measured by CT or MRI.
Time Frame: Assessed at end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug
|
measurement of stable disease
|
Assessed at end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug
|
Evaluate progression-free survival (PFS)
Time Frame: Responses and survival assessed, at the end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug
|
measurement of PFS
|
Responses and survival assessed, at the end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug
|
Evaluate overall survival (OS)
Time Frame: Assessed by telephone call at end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug
|
measurement of OSS
|
Assessed by telephone call at end of C2 and every 2 cycles thereafter through 6 months following last dose of study drug
|
Evaluate the mean plasma concentrations of FF-10502-01
Time Frame: Assessed at Cycle 1 Day 1, and Cycle 1 Day 15
|
measurement of plasma concentrations
|
Assessed at Cycle 1 Day 1, and Cycle 1 Day 15
|
Evaluate FF-10502-01 incorporation into whole blood cellular DNA by LC-MS/MS as a pharmacodynamic marker
Time Frame: Assessed at Cycle 1 Day 1, Cycle 1 Day , Cycle 1 Day 15, Cycle 1, Day 22, Cycle 2 Day 1, at the end of Cycle 2 and ever 2 cycles thereafter up to 24 weeks.
|
measurement of cellular DNA
|
Assessed at Cycle 1 Day 1, Cycle 1 Day , Cycle 1 Day 15, Cycle 1, Day 22, Cycle 2 Day 1, at the end of Cycle 2 and ever 2 cycles thereafter up to 24 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Filip Janku, MD, University of Texas MD Anderson Center
- Principal Investigator: Gerald Falchook, MD, Sarah Cannon Research Institute-Denver
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2016
Primary Completion (Actual)
November 5, 2020
Study Completion (Actual)
November 5, 2020
Study Registration Dates
First Submitted
January 13, 2016
First Submitted That Met QC Criteria
January 19, 2016
First Posted (Estimate)
January 22, 2016
Study Record Updates
Last Update Posted (Actual)
April 13, 2022
Last Update Submitted That Met QC Criteria
April 5, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FF1050201US101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
Clinical Trials on FF-10502-01
-
Fujifilm Pharmaceuticals U.S.A., Inc.CompletedAML | MDS | CMMLUnited States
-
Fujifilm Pharmaceuticals U.S.A., Inc.CompletedAML, AdultUnited States
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.RecruitingBreast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostatic CancerChina
-
Fujifilm Pharmaceuticals U.S.A., Inc.WithdrawnMyelodysplastic Syndrome (MDS)
-
GlaxoSmithKlineHammersmith Medicines ResearchCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
GlaxoSmithKlineCompletedAsthmaArgentina, Russian Federation, United States, Chile, Thailand
-
Guy's and St Thomas' NHS Foundation TrustUnknown
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Centre Hospitalier William Morey - Chalon sur SaôneCentre Hospitalier Universitaire DijonRecruitingCritically Ill | Central Venous Catheter Associated Bloodstream Infection | Healthcare Associated InfectionFrance